Mirena®
(52mg intrauterine delivery system Levonorgestrel)
Up to 8 years of highly effective contraception
Mirena® a hormonal intrauterine system that provides contraceptive protection for up to 8 years and treatment of heavy menstrual bleeding (If symptoms have not returned after 5 years of use, continued use of the system may be considered. Mirena should be removed or replaced after 8 years at the latest.). It is inserted into the uterus and releases the hormone levonorgestrel in small doses (20 μg/24 hours) into the uterine cavity.
Mirena® has the broadest range of indications and the longest licensed duration of action for an IUS, offering
5 years of effective relief from HMB
(If symptoms have not returned after 5 years of use, continued use of the system may be considered. Mirena should be removed or replaced after 8 years at the latest.)
8 years of Contraceptive efficacy
5 years of Endometrial Protection
during oestrogen replacement therapy.
Mirena® therapeutic indications
- Contraception
- Idiopathic Menorrhagia:Mirena® may be particularly useful in women with idiopathic menorrhagia requiring (reversible) contraception.
- Endometrial Protection:Protection from endometrial hyperplasia during oestrogen replacement therapy.
Mirena® opens out to a T-shaped plastic frame with a cylinder-shaped reservoir around the vertical arm of the frame.
The reservoir contains the progestogen levonorgestrel.
The size of Mirena® is approximately 32 mm x 32 mm.
Patient Booklet for Mirena®
A digital guide to your Mirena®. This leaflet is intended for women who have been prescribed Mirena®. Please read the patient information leaflet (PIL) included in the Mirena® box for full details.
Mirena® is a trusted choice for you and your patients
Over 26 years
of clinical experience
More than 945 clinical trials
and 4300 peer-reviewed publications to date
An estimated 57.5 million
insertions worldwide
Mirena® has high rates of patient satisfaction
The contraceptive effect of Mirena® is based on a local effect of levonorgestrel:
of HMB patients are satisfied with Mirena
A total of 647 patients (LNG-IUS [n=437], CMTs [n=135]) diagnosed with HMB were recruited to this non-interventional study from the eight participating countries in Asia. Patient satisfaction was recorded at the last visit (at 12 months or premature discontinuation). At each visit (at 3, 6, and 12 months), patients completed the menorrhagia multi-attribute scale to assess health related quality of life.
Adapted from: Xu L, et al. International Journal of Women’s Health. 2014;6:547–554.
95% of first-time users of Mirena® for contraception are satisfied, rising to 99% of those on their second Mirena® IUS
Women who had used the LNG-IUS for six months or more completed a standardised questionnaire on reasons for use, user satisfaction and other aspects. A total of 8680 questionnaires were completed by survey participants in 18 countries across Europe and the Near East. The average woman using the LNG-IUS was 38 years old, was married or lived with her partner, and had two children. Overall, 95% of patients were satisfied with the LNG-IUS; the percentage rose to 99% among those using their second LNG-IUS. Reasons mentioned for using the LNG-IUS included the need for contraception (68%), its high efficacy (59%) and the shorter/lighter menstrual bleeding (55%). Of the women with prior bleeding problems, 93% reported an improvement in their symptoms with the LNG-IUS. Participants also rated the reliability, tolerability and convenience of the method highly.
Adapted from: Romer T and Linsberger D. The European Journal of Contraception and Reproductive Health Care. 2009;14(6):391–398.
PP-MIR-IE-0069-1 | January 2026